Recurrent events: fatal or non‐fatal (same type of stroke, i.e. ischaemic or haemorrhagic) · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in primary outcome measure: recurrent stroke (non‐fatal or fatal) compared with medical therapy (low certainty).
1 finding from 1 review
Primary outcome measure: recurrent stroke (non‐fatal or fatal) stratified by the type of device studied ‐ Amplatzer PFO occluder · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in primary outcome measure: recurrent stroke (non‐fatal or fatal)… compared with medical therapy (low certainty).
1 finding from 1 review
Death from any cause (secondary outcome 3) · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in secondary outcome: all‐cause mortality at the end of compared with medical therapy (low certainty).
1 finding from 1 review
Secondary outcome:total serious adverse events at the end of · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in secondary outcome:total serious adverse events at the end of compared with medical therapy (low certainty).
1 finding from 1 review
Secondary outcome: the incidence of atrial fibrillation · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC probably leads to higher secondary outcome: the incidence of atrial fibrillation compared with medical therapy (moderate certainty).
1 finding from 1 review
Time‐to‐event analyses for recurrent stroke · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in time‐to‐event analyses for recurrent stroke compared with medical therapy (low certainty).
1 finding from 1 review
Time‐to‐event analyses for recurrent stroke stratified by the type of device ‐ Amplatzer PFO occluder · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in time‐to‐event analyses for recurrent stroke stratified by the type… compared with medical therapy (moderate certainty).
1 finding from 1 review
Death at 6 to 12 months · malignant cerebral oedema after ischaemic stroke
Summary of findings table ‐ surgical decompression leads to lower death at 6 to 12 months compared with medical treatment alone (high certainty).
1 finding from 1 review
Death or severe disability (mRS > 4) at 6 to 12 months · malignant cerebral oedema after ischaemic stroke
Summary of findings table ‐ surgical decompression leads to lower death or severe disability (mRS > 4) at 6 to 12 months compared with medical treatment alone (high certainty).
1 finding from 1 review
Death or moderate disability (mRS > 3) at 6 to 12 months · malignant cerebral oedema after ischaemic stroke
Summary of findings table ‐ surgical decompression probably leads to lower death or moderate disability (mRS > 3) at 6 to 12 months compared with medical treatment alone (moderate certainty).
1 finding from 1 review
Severe disability (mRS = 5) at 6 to 12 months · malignant cerebral oedema after ischaemic stroke
Summary of findings table ‐ surgical decompression showed no clear difference in severe disability (mRS = 5) at 6 to 12 months compared with medical treatment alone (low certainty).
1 finding from 1 review
Adverse events · malignant cerebral oedema after ischaemic stroke
1 finding from 1 review
Hydrocephalus · malignant cerebral oedema after ischaemic stroke
1 finding from 1 review
Reoperation · malignant cerebral oedema after ischaemic stroke
1 finding from 1 review
Functional outcomes · people with stroke upon awakening
Intravenous thrombolytic treatment leads to higher independent functional outcome at end of compared with standard medical care (high certainty).
1 finding from 1 review
Symptomatic intracranial haemorrhage at · people with stroke upon awakening
Intravenous thrombolytic treatment showed no clear difference in symptomatic intracranial haemorrhage at compared with standard medical care (high certainty).
1 finding from 1 review
Death at · people with stroke upon awakening
Intravenous thrombolytic treatment showed no clear difference in death at compared with standard medical care (high certainty).
1 finding from 1 review
Functional outcomes · people with stroke upon awakening
Endovascular treatment leads to higher independent functional outcome at end of compared with standard medical care (high certainty).
1 finding from 1 review
Intracranial haemorrhage · people with stroke upon awakening
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death at · people with stroke upon awakening
Endovascular treatment showed no clear difference in death at compared with standard medical care (high certainty).
1 finding from 1 review